-
1
-
-
84862894846
-
Pertuzumab monotherapy after trastuzumabbased treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
-
Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumabbased treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:1594-1600.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1594-1600
-
-
Cortés, J.1
Fumoleau, P.2
Bianchi, G.V.3
-
2
-
-
80052593511
-
HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis
-
Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat. 2011;129:659-674.
-
(2011)
Breast Cancer Res Treat
, vol.129
, pp. 659-674
-
-
Houssami, N.1
Macaskill, P.2
Balleine, R.L.3
Bilous, M.4
Pegram, M.D.5
-
3
-
-
84868520609
-
Trastuzumab emtansine for HER2-positive advanced breast cancer
-
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
-
(2012)
N Engl J Med
, vol.367
, pp. 1783-1791
-
-
Verma, S.1
Miles, D.2
Gianni, L.3
-
4
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
5
-
-
84891781085
-
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
-
Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277-289.
-
(2014)
Eur J Cancer
, vol.50
, pp. 277-289
-
-
Aurilio, G.1
Disalvatore, D.2
Pruneri, G.3
-
6
-
-
78650986693
-
HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression
-
Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125:553-561.
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 553-561
-
-
Wilking, U.1
Karlsson, E.2
Skoog, L.3
-
7
-
-
84893691711
-
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
-
Karlsson E, Sandelin K, Appelgren J, et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Eur J Cancer. 2014;50:517-524.
-
(2014)
Eur J Cancer
, vol.50
, pp. 517-524
-
-
Karlsson, E.1
Sandelin, K.2
Appelgren, J.3
-
8
-
-
84864085607
-
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression
-
Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-2608.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2601-2608
-
-
Lindström, L.S.1
Karlsson, E.2
Wilking, U.M.3
-
9
-
-
84906053842
-
111 In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment
-
Gaykema SB, de Jong JR, Perik PJ, et al. 111In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014;13.
-
(2014)
Mol Imaging
, vol.13
-
-
Gaykema, S.B.1
De Jong, J.R.2
Perik, P.J.3
-
10
-
-
77951474500
-
89 Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer
-
Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 586-592
-
-
Dijkers, E.C.1
Oude Munnink, T.H.2
Kosterink, J.G.3
-
11
-
-
77954963897
-
111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold
-
Ahlgren S, Orlova A, Wallberg H, et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010;51:1131-1138.
-
(2010)
J Nucl Med
, vol.51
, pp. 1131-1138
-
-
Ahlgren, S.1
Orlova, A.2
Wallberg, H.3
-
12
-
-
77956176686
-
Structural basis for high-affinity HER2 receptor binding by an engineered protein
-
Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA. 2010;107:15039-15044.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 15039-15044
-
-
Eigenbrot, C.1
Ultsch, M.2
Dubnovitsky, A.3
Abrahmsen, L.4
Hard, T.5
-
13
-
-
77951768789
-
Design of an optimized scaffold for affibody molecules
-
Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol. 2010;398:232-247.
-
(2010)
J Mol Biol
, vol.398
, pp. 232-247
-
-
Feldwisch, J.1
Tolmachev, V.2
Lendel, C.3
-
14
-
-
84901325574
-
111In-ABY-025 affibody molecule
-
Sörensen J, Sandberg D, Sandstrom M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55:730-735.
-
(2014)
J Nucl Med
, vol.55
, pp. 730-735
-
-
Sörensen, J.1
Sandberg, D.2
Sandstrom, M.3
-
15
-
-
79953766951
-
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
-
Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38:531-539.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 531-539
-
-
Tolmachev, V.1
Wallberg, H.2
Sandstrom, M.3
Hansson, M.4
Wennborg, A.5
Orlova, A.6
-
16
-
-
84861861669
-
Tumor targeting using Affibody molecules: Interplay of affinity, target expression level, and binding site composition
-
Tolmachev V, Tran TA, Rosik D, Sjoberg A, Abrahmsen L, Orlova A. Tumor targeting using Affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012;53: 953-960.
-
(2012)
J Nucl Med
, vol.53
, pp. 953-960
-
-
Tolmachev, V.1
Tran, T.A.2
Rosik, D.3
Sjoberg, A.4
Abrahmsen, L.5
Orlova, A.6
-
17
-
-
84954520777
-
68Ga]ABY-025 Affibody PET/CT
-
Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016;6:262-271.
-
(2016)
Theranostics
, vol.6
, pp. 262-271
-
-
Sörensen, J.1
Velikyan, I.2
Sandberg, D.3
-
18
-
-
84938362385
-
GMP compliant preparation of a 68gallium-labeled Affibody analogue for breast cancer patient examination: Firstin-man
-
Velikyan I, Wennborg A, Feldwisch J, et al. GMP compliant preparation of a 68gallium-labeled Affibody analogue for breast cancer patient examination: firstin-man. Eur J Nucl Med Mol Imaging. 2014;41(suppl):S228-S229.
-
(2014)
Eur J Nucl Med Mol Imaging
, vol.41
, pp. S228-S229
-
-
Velikyan, I.1
Wennborg, A.2
Feldwisch, J.3
-
19
-
-
2442649352
-
68 Ga bioconjugates with high specific radioactivity
-
Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-560.
-
(2004)
Bioconjug Chem
, vol.15
, pp. 554-560
-
-
Velikyan, I.1
Beyer, G.J.2
Langstrom, B.3
-
20
-
-
67349222944
-
177Lu-DOTA0,Tyr3]octreotate
-
Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-1146.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 1138-1146
-
-
Forrer, F.1
Krenning, E.P.2
Kooij, P.P.3
-
21
-
-
0030002992
-
MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
-
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
-
(1996)
J Nucl Med
, vol.37
, pp. 538-546
-
-
Stabin, M.G.1
-
23
-
-
23044470017
-
OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine
-
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
-
(2005)
J Nucl Med
, vol.46
, pp. 1023-1027
-
-
Stabin, M.G.1
Sparks, R.B.2
Crowe, E.3
-
24
-
-
84859648576
-
89Zr-ibritumomab tiuxetan and PET
-
Rizvi SN, Visser OJ, Vosjan MJ, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39:512-520.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 512-520
-
-
Rizvi, S.N.1
Visser, O.J.2
Vosjan, M.J.3
-
25
-
-
1542438683
-
-
Chapter I: Food and Drug Administration Department of Health and Human Services. Subchapter D: Drugs for Human Use. Part 361: Prescription Drugs for Human Use Generally Recognized as Safe and Effective and Not Misbranded - Drugs Used in Research. Accessed February 25, 2016
-
Title 21: Food and drugs. Chapter I: Food and Drug Administration Department of Health and Human Services. Subchapter D: Drugs for Human Use. Part 361: Prescription Drugs for Human Use Generally Recognized as Safe and Effective and Not Misbranded - Drugs Used in Research. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart5361&showFR51. Accessed February 25, 2016.
-
Food and Drugs
-
-
Title 211
|